Providing Natural Biomaterial Solutions for patients suffering from challenging soft tissue loss.

NEWS.


November 19, 2013
The mnufacturing facility of the first Medical Grade Batch of AST001, in production now in Baltimore.




November 7, 2012
Baltimore, November 7, 2012: Aegeria Soft Tissue (AST) appoints Dr. Patrick Byrne acting Chief Medical officer.

Dr Patrick Byrne has been appointed acting CMO and will supervise the clinical testing of the first A3T01 (Aegeria Acellularized Adipose Tissue 01). A3T01 is an injectable form of acellular adipose tissue designed for soft tissue reconstruction. Clinical testing will take place at the Cosmetic Surgery Center of Maryland. Dr. Byrne is board certified in facial plastic surgery by both the American Board of Otolaryngology and the American Board of Facial Plastic and Reconstructive Surgery and is a leading authority on nasal surgery (rhinoplasty), rejuvenation of the aging face (facelift, necklift, blepharoplasty, browlift, etc.), skin cancers, and the treatment of facial paralysis (facial reanimation).


October 20, 2011 - Press Release n1
Aegeria Soft Tissue completes the industrial prototyping of A3T01, its lead product.

Aegeria Soft Tissue LLC ("AST"), a Baltimore startup cofounded by Dr. Jennifer Elisseeff, has completed the prototyping stage of A3T01*, its lead product, and is moving forward to scale-up production in preparation for a 2012 product launch.
A3T01 is a soft tissue support allograft created by Dr. Elisseeff's laboratory from human adipose tissue, or fat. It offers an exciting new alternative to the synthetic or polymer biomaterials currently on the market. The product's physical and biological characteristics are similar to natural soft tissue in the body, and early studies show a strong ability for A3T01 to fill deformities.
"We have completed the prototyping stage, and we are confident that AST will be able to start clinical trials said Dr. Elisseeff, Director of the Translational Tissue Engineering Center at Johns Hopkins School of Medicine.

A3T01 may have a broad social and medical impact, since it is a naturally occurring biomaterial (fat tissue derived matrix ) that is designed to replace soft tissue loss volume in cases of significant tissue loss, such as that which may occur from trauma (ie. burns, battlefield injury, accidents), cancer (ie. lumpectomy), AIDS, or surgery.

AEGERIA SOFT TISSUE LLC is a Baltimore-based startup formed to commercialize highly innovative tissue reconstruction technologies invented by Dr. Jennifer Elisseeff. The Company is privately financed. The product and the processes needed for its manufacturing are protected by two patent applications exclusively licensed to AST.

This press release contains forward-looking statements from AST that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements such as unexpected delays in time to clinical testing and time to market.

Contact : jhe@aegeriasoftissue.com


October 1, 2011
Aegeria announces the closing of Series A
On October 1, 2011, Aegerial Soft Tissue LLC announced that it was closing its Series A round of financing. The Company has issued its Series A Preferred Units to seven investors, including the Founders, two prominent ENR surgeons, the family trust for the Controlling Shareholders of a European Industrial Company , and a prominent International economist. The Company believes its current funding will be sufficient until the end of 2012.